| 2.365 -0.135 (-5.4%) | 01-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.59 |
1-year : | 4.13 |
| Resists | First : | 3.07 |
Second : | 3.53 |
| Pivot price | 2.66 |
|||
| Supports | First : | 2.32 |
Second : | 1.93 |
| MAs | MA(5) : | 2.57 |
MA(20) : | 2.71 |
| MA(100) : | 4.27 |
MA(250) : | 6.92 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3  |
| %K %D | K(14,3) : | 6.2 |
D(3) : | 10.6 |
| RSI | RSI(14): 31 |
|||
| 52-week | High : | 21 | Low : | 2.32 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ACXP ] has closed below the lower bollinger band by 5.9%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ ACXP ] is to continue within current trading range. It is unclear right now based on current values. 73.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 14 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.57 - 2.6 | 2.6 - 2.61 |
| Low: | 2.28 - 2.31 | 2.31 - 2.32 |
| Close: | 2.33 - 2.38 | 2.38 - 2.41 |
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Wed, 21 Jan 2026
Loss-Making Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Expected To Breakeven In The Medium-Term - Yahoo Finance
Fri, 16 Jan 2026
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Tue, 06 Jan 2026
Has Acurx Pharmaceuticals (ACXP) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Mon, 27 Oct 2025
Acurx Pharmaceuticals (NASDAQ: ACXP) sets Nov 12 call on Q3 2025 results, business update - Stock Titan
Thu, 09 Oct 2025
Acurx Pharmaceuticals granted Australian patent for antibiotics - Investing.com
Wed, 08 Oct 2025
Why Are Pharmaceutical Stocks XBIO, UPC, XTLB, & ACXP Up Today? - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 6.1 (%) |
| Held by Institutions | 7 (%) |
| Shares Short | 81 (K) |
| Shares Short P.Month | 13 (K) |
| EPS | -8.19 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.01 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -95.7 % |
| Return on Equity (ttm) | -291.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.29 |
| PEG Ratio | 0 |
| Price to Book value | 1.17 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.71 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|